LivaNova PLC (NASDAQ:LIVN) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• LivaNova has a “Moderate Buy” consensus rating from 11 analysts: six buys, four holds and one strong buy. The average 12-month price target is $83.50, compared with a recent share price of $80.84.
• The company exceeded quarterly expectations, reporting $1.26 in EPS versus a $1.09 consensus estimate and revenue of $390.59 million, up 10.8% year over year.
• Institutional investors own 97.64% of LivaNova’s shares, while insiders own 0.35%; director Francesco Bianchi recently sold 1,800 shares at an average price of $75.75.

Shares of LivaNova PLC (NASDAQ:LIVN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $83.50.

A number of brokerages recently issued reports on LIVN. Weiss Ratings restated a "hold (c)" rating on shares of LivaNova in a research note on Tuesday, August 4th. Needham & Company LLC lifted their target price on shares of LivaNova from $81.00 to $93.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a research report on Wednesday, August 5th. Freedom Capital raised shares of LivaNova to a "hold" rating in a research report on Tuesday, June 30th. Finally, Mizuho upped their price target on shares of LivaNova from $90.00 to $95.00 and gave the company an "outperform" rating in a research note on Wednesday, July 15th.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director owned 7,228 shares of the company's stock, valued at $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.35% of the stock is owned by insiders.

Hedge Funds Weigh In On LivaNova

Several hedge funds have recently made changes to their positions in LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of LivaNova by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company's stock valued at $1,394,000 after purchasing an additional 1,360 shares during the period. Goldman Sachs Group Inc. grew its holdings in LivaNova by 4.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company's stock valued at $32,012,000 after buying an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in LivaNova by 10.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company's stock valued at $6,633,000 after buying an additional 15,405 shares in the last quarter. Intech Investment Management LLC increased its position in shares of LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company's stock valued at $1,724,000 after buying an additional 7,195 shares during the period. Finally, Strs Ohio bought a new stake in shares of LivaNova during the first quarter valued at about $130,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Price Performance

LIVN opened at $80.84 on Thursday. The firm has a market cap of $4.45 billion, a P/E ratio of 23.92 and a beta of 0.86. The firm has a 50-day moving average of $80.60 and a 200 day moving average of $71.74. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. LivaNova has a fifty-two week low of $48.82 and a fifty-two week high of $85.76.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.09 by $0.17. The business had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The company's revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.05 earnings per share. On average, research analysts expect that LivaNova will post 3.77 EPS for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source